Trial · NCT02820844
Participant flow54
How many started, completed or left each group, period by period.
1 to 20 of 54
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-blinded (Up to 48 Weeks) | STARTED | Treatment Cycle 1: Placebo | 124 | |
| Double-blinded (Up to 48 Weeks) | STARTED | Treatment Cycle 1: GSK1358820 100 U | 124 | |
| Double-blinded (Up to 48 Weeks) | STARTED | Treatment Cycle 2: Placebo / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | STARTED | Treatment Cycle 2: GSK1358820 100 U / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | STARTED | Treatment Cycle 3: Placebo / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | STARTED | Treatment Cycle 3: GSK1358820 100 U / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | COMPLETED | Treatment Cycle 1: Placebo | 119 | |
| Double-blinded (Up to 48 Weeks) | COMPLETED | Treatment Cycle 1: GSK1358820 100 U | 115 | |
| Double-blinded (Up to 48 Weeks) | COMPLETED | Treatment Cycle 2: Placebo / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | COMPLETED | Treatment Cycle 2: GSK1358820 100 U / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | COMPLETED | Treatment Cycle 3: Placebo / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | COMPLETED | Treatment Cycle 3: GSK1358820 100 U / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | NOT COMPLETED | Treatment Cycle 1: Placebo | 5 | |
| Double-blinded (Up to 48 Weeks) | NOT COMPLETED | Treatment Cycle 1: GSK1358820 100 U | 9 | |
| Double-blinded (Up to 48 Weeks) | NOT COMPLETED | Treatment Cycle 2: Placebo / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | NOT COMPLETED | Treatment Cycle 2: GSK1358820 100 U / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | NOT COMPLETED | Treatment Cycle 3: Placebo / GSK1358820 100 U | 0 | |
| Double-blinded (Up to 48 Weeks) | NOT COMPLETED | Treatment Cycle 3: GSK1358820 100 U / GSK1358820 100 U | 0 | |
| Open-label(2nd Treatment-Up to 48 Weeks) | STARTED | Treatment Cycle 1: Placebo | 0 | |
| Open-label(2nd Treatment-Up to 48 Weeks) | STARTED | Treatment Cycle 1: GSK1358820 100 U | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02820844/flow